Search for European Projects

28 European Projects Found

Searched on 125080 European Projects

 FINISHED 

European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry (EN_ACTI2NG)

Start date: Jan 1, 2017, End date: Dec 31, 2020,

The EN-ACTI2NG program (European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry) emanates from the recent clinical evidence that T cells expressing engineered tumor-specific immune receptors can eradicate certain tumors that do not respond to conventional treatment. To obtain T cells with reactivity to a wider array of tumors an ...
Read Project

 11

 FINISHED 

Professional cross-priming for ovary and prostate cancer (PROCROP)

Start date: Sep 1, 2015, End date: Aug 31, 2020,

Immune responses are initiated by antigen presentation mediated by dendritic cells (DC). There is a minority subset of DC highly specialised in starting up cytotoxic T lymphocytes able to kill tumor cells. PROCROP aims to develop in three pilot clinical trials a suitable individualized cancer vaccine technology for castration resistant prostate cancer and metastatic cancer of the ovary that would ...
Read Project

 8

 FINISHED 

New experimental therapeutic approaches for Parkinson’s disease by direct DA neuronal reprogramming (REPROPARK)

Start date: Jun 1, 2014, End date: May 31, 2019,

Neurodegenerative diseases cause a significant burden on the elderly population in Europe. Parkinson’s disease (PD) affects 1.2 million people in Europe and with the increasing life expectancy this number will rise, putting more pressure on health care. Treatment of PD is only symptomatic, and therefore, there is an urgent need for more efficient therapies. Degeneration of mesencephalic DA neurons ...
Read Project

 2

 FINISHED 

Heart OMics in AGEing (HOMAGE)

Start date: Feb 1, 2013, End date: Jan 31, 2019,

As more people survive into old age, the prevalence of heart failure (HF), one of the most common and debilitating diseases in older people, will rise still further. Delaying or preventing HF will have great benefit to those at personal risk, their families, society and the economy. HOMAGE aims to provide a biomarker (BM) approach that will a) help identify i. patients at high risk of developing ...
Read Project

 22

 FINISHED 

Functional and Mecahnistic Roles of Large Intergenic Non-coding RNAs in Cancer (CANCERLINC)

Start date: Jan 1, 2012, End date: Dec 31, 2017,

Mammalian cells express thousands of RNA molecules structurally similar to protein coding genes –they are large, spliced, poly-adenylated, transcribed by RNA Pol II, with conserved promoters and exonic structures –however lack coding capacity. Although thousands exist, only few of these large intergenic non-coding RNAs (lincRNAs) have been characterized. The few that have, show powerful biological ...
Read Project

 1

 FINISHED 

Characterization of Key Epigenetic Targets in Hepatic Fibrosis and Hepatocellular Carcinoma Development. Generation of New Antifibrotic and Antitumoral Drugs. (TARGEPILIVER)

Start date: Dec 1, 2015, End date: Nov 30, 2017,

Liver fibrosis represents a common pathogenic pathway in most chronic liver diseases (CLDs) and cirrhosis, its end stage, is a huge healthcare burden. The main causes of CLD are chronic viral hepatitis B or C infection, alcohol abuse and obesity-linked steatohepatitis, conditions with increasing global incidence. Hepatocellular carcinoma (HCC) develops on this background of CLD as a multistep proc ...
Read Project

 1

 FINISHED 

Immunostimulatory Agonist antibodies for Cancer Therapy (IACT)

Start date: Nov 1, 2013, End date: Oct 31, 2017,

"This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of cytotoxic regimens is enhanced by simultaneous application of drugs that strengthen the immune system. The recent FDA-approval of Ipilimumab demonstrated that cancer immun ...
Read Project

 11

 FINISHED 

The role of miRNAs in KRAS-driven Non-Small Cell Lung Cancer (KRASmiR)

Start date: Oct 1, 2013, End date: Sep 30, 2017,

Lung cancer is the leading cause of death by cancer in Europe. Non-small cell lung cancer (NSCLC) represents about 80% of total lung cancers. KRAS is the most commonly mutated oncogene in NSCLC, found in over 20% of patients. Since KRAS mutations are directly responsible for NSCLC, KRAS represents a relevant target to prevent NSCLC development. Yet, efforts to develop therapeutic inhibitors have f ...
Read Project

 1

 FINISHED 

The European non-coding RNA network (RNATRAIN)

Start date: Oct 1, 2013, End date: Sep 30, 2017,

"Non-coding RNA (ncRNA) is a new research field in rapid development. It holds the potential to explain many fundamental biological phenomena and there is a vast prospective for the development of ncRNA-derived diagnostic and therapeutic tools. Hence, biotech and pharmaceutical companies are actively looking into this unexplored territory for novel targets. Therefore, there is a substantial and un ...
Read Project

 11

 FINISHED 

Targeting cardiac fibrosis for heart failure treatment (FIBRO-TARGETS)

Start date: Sep 1, 2013, End date: Aug 31, 2017,

The Fibro-Targets project is a multi-disciplinary 4 years program involving 10 partners ambitioning “the identification, characterisation and validation of in vitro and in vivo models of novel therapeutically relevant targets” for myocardial interstitial fibrosis (MIF) in heart failure. The project is based on the hypothesis that the intervention on novel fibrosis-related targets involved in the p ...
Read Project

 11

 FINISHED 

Supply-rate depression as endogenous anti-epileptic mechanism (ENDOGENOUS AED)

Start date: Sep 1, 2012, End date: Aug 24, 2017,

Epilepsy is a prevalent neurological disorder affecting more than 1 % of all people, with the estimated number of 900,000 children and adolescents suffering from active epilepsy in Europe. Most current drugs targeting this disease have important adverse side-effects. An ideal drug would, however, potentiate the endogenous anti-seizure mechanisms that keep most humans epilepsy-free.To date, these n ...
Read Project

 2

 FINISHED 

"From Brain Gene Transfer Towards Gene Therapy: Pharmacological Assessment of AAV, CAV and LVV" (BRAINVECTORS)

Start date: Nov 1, 2012, End date: Oct 31, 2016,

"BRAINVECTORS aims devising new gene therapy(GT)-based treatments for Parkinson’s and other neurodegenerative diseases, in substitution of current systemic treatments, by delivering neurotrophic factors (GDNF) into the CNS with new vectors derived from adeno-associated (AAV), canine adenoviruses (CAV) and lentiviruses (LV) with inducible gene expression.Although AAV, CAV and LVV are considered acc ...
Read Project

 12

 FINISHED 

Role of DNA methylation in the regulation of lincRNAs in Hematological Malignancies (LincMHeM)

Start date: Sep 1, 2013, End date: Aug 31, 2016,

"Traditionally, cancer researchers have focused their best efforts on studying the genetic alterations affecting the coding genes. Subsequently, it was observed that in addition to genetic alterations, epigenetic alterations affecting coding genes play an important role in tumor development. In the last decade, largely due to the ability to sequence the human genome and the observation that much o ...
Read Project

 1

 FINISHED 

The MEtabolic Road to DIAstolic Heart Failure (MEDIA)

Start date: Jan 1, 2011, End date: Jun 30, 2016,

More than 50% of heart failure (HF) patients present without a major deficit of left ventricular (LV) systolic function and are presumed to suffer from diastolic HF (DHF) because diastolic LV distensibility is usually impaired in these patients. The vast majority (~80%) of DHF patients is exposed to metabolic risk factors. The MEDIA consortium therefore investigates:1) how metabolic derangements c ...
Read Project

 23

 FINISHED 

Markers for Sub-Clinical Cardiovascular Risk Assessemnt (EU-MASCARA)

Start date: Dec 1, 2011, End date: May 31, 2016,

EU-MASCARA is a collaborative project that aims to improve diagnosis of cardiovascular diseases and prediction of cardiovascular risk by analysing a panel of biomarkers. EU-MASCARA aims to examine genetic, proteomic and metabolomic markers together with markers of inflammation, oxidative stress and cardiac remodelling to study their incremental diagnostic and predictive value over and above existi ...
Read Project

 16

 FINISHED 

Interspecies endotheliarization for organ xenotransplantation (INTEREXT)

Start date: Apr 1, 2014, End date: Apr 12, 2016,

Organ transplantation is an efficient approach or remedying end-life diseases that cannot be treated by other methods. Nevertheless, the available organs do not cover the clinical demand. As an alternative to the transplantation human organs, the xenotransplantation of animals’ organs has been proposed. Unfortunately, despite the big effort of the last decades, organs are severely rejected upon xe ...
Read Project

 1

 FINISHED 

ROLE OF THE TRANSCRIPTION FACTOR FOXP1 IN B CELL FUNCTION AND LYMPHOMAGENESIS (LYMFOXP1)

Start date: Nov 1, 2013, End date: Apr 8, 2016,

"FOXP1 (Forkhead box-P1) is a winged-helix transcription factor that has been demonstrated to be expressed in a subset of activated B-cell type (ABC) diffuse B-cell lymphomas (DLBCLs). Strong FOXP1 expression appears to have an additive adverse role in the pathogenesis and clinical behavior of ABC-DLBCL. We believe that a better understanding of the molecular impact of FOXP1 deregulation in DLBCL ...
Read Project

 1

 FINISHED 

NEW ADVANCED VACCINES IN CHRONIC HEPATITIS B (NAVICHEB)

Start date: Apr 1, 2011, End date: Mar 31, 2015,

"Despite effective vaccines, hepatitis B virus (HBV) infection remains a major health problem with 2 billion people infected worldwide. Among them, 350 million are chronically infected, a major risk factor for development of hepatocellular carcinoma (HCC). A new and efficient treatment against chronic infection and HCC is strongly needed, and therefore it is important to understand HBV replication ...
Read Project

 1

 FINISHED 

The roles of juvenile NMDA receptors in synapse maturation and elimination and their association with cognition (NMDAR-synprun)

Start date: Mar 1, 2013, End date: Feb 28, 2015,

The aim of the project is to understand how the NMDA receptor subunit NR3A is involved in selective synapse elimination (“pruning”) during development and how the abnormal expression of NR3A found in mental disorders such as Schizophrenia, Alzheimer´s disease and Huntington correlates with the reduction of functional synapses and deficits in the cognitive function. Importantly, the Host lab has al ...
Read Project

 1

 FINISHED 

Augmenting PBGD expression in the liver as a Novel Gene therapy for Acute Intermittent Porphyria (AIPGENE)

Start date: Jan 1, 2011, End date: Oct 31, 2014,

Acute intermittent porphyria (AIP) is a rare genetic disease in which mutations in the porphobilinogen deaminase (PBGD) gene produce insufficient activity of a protein necessary for heme synthesis. This leads to an accumulation of toxic intermediates resulting in a wide variety of problems including acute, severe abdominal pains, psychiatric and neurological disorders, and muscular weakness. Acute ...
Read Project

 8

 FINISHED 

Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis (CURELUNG)

Start date: Jan 1, 2011, End date: Jun 30, 2014,

"Lung cancer (LC) is still the most lethal type of cancer worldwide. The extremely poor prognosis for LC patients is partly due to the lack of effective therapies. At present, most patients with pulmonary carcinomas are treated with chemotherapy. This essentially consists of classic cytotoxic drugs which only improve survival in small cohorts in few cases. In spite of the rapidly growing understan ...
Read Project

 11

 FINISHED 

Host and viral factors in acute hepatitis C (HEPACUTE)

Start date: Nov 1, 2010, End date: Apr 30, 2014,

Chronic hepatitis C is one of the most common chronic viral infections of humans and a major cause of chronic liver disease, cirrhosis and liver cancer. Still about 4 million new infections occur world-wide each year with 50-85% of patients progressing to chronic hepatitis C. Currently there is no marker to predict spontaneous viral clearance and to guide treatment decisions.The major objectives o ...
Read Project

 17

 FINISHED 

Evaluation of metastatic and angiogenic potential of cancer stem-like cells in distinct mouse models for lung and liver metastasis (Metastasis)

Start date: Nov 1, 2011, End date: Mar 5, 2014,

Metastasis disease is the leading cause of cancer-related mortality with very few effective treatment options available for patients. Metastases are characterized by the presence of vascular proliferation, a subpopulation of stem-like cells and infiltration by various bone marrow derive cells (BMDCs). BMDCs have been shown to provide the premetastatic niches that promote the angiogenic process a ...
Read Project

 1

 FINISHED 

Restorative Plasticity At Corticostriatal Excitatory Synapses (REPLACES)

Start date: Nov 1, 2008, End date: Apr 30, 2013,

"Long-lasting, activity-dependent synaptic changes are thought to underlie the ability of the brain to translate experiences into memories and seem to represent the cellular model underlying learning and memory processes. Alteration of brain plasticity may lead to the motor and cognitive disturbances observed in neurodegenerative diseases. Therapeutic approaches targeting synaptic plasticity could ...
Read Project

 12

 FINISHED 

Longitudinal analysis to study neurodegenerative diseases mechanisms in specific neuronal subtypes (Neuronal Specificity)

Start date: May 1, 2009, End date: Apr 30, 2013,

Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) are the most common human neurodegenerative diseases. Each features an abnormal accumulation of proteins, but whether the aggregation leads to neuronal death is controversial. HD is caused by a single mutation that increases the number of CAG repeats. Mutant huntingtin (htt) forms intraneuronal inclusion bodies (IBs). ...
Read Project

 1

 FINISHED 

NONHUMAN ADENOVIRUS VECTORS FOR GENE TRANSFER TO THE BRAIN (BrainCAV)

Start date: Oct 1, 2008, End date: Mar 31, 2013,

Formidable challenges remain to prevent and treat successfully neurodegenerative diseases. Traditional pharmacological approaches, as well as those using stem cells, have made progress but their impact remain limited. As suggested by clinical results in Canavan and Parkinson’s disease, gene transfer offers substantial potential. However, this strategy of therapeutic intervention also brings unique ...
Read Project

 12

 FINISHED 

European Network for Cell Imaging and Tracking Expertise (ENCITE)

Start date: Jun 1, 2008, End date: Nov 30, 2012,

"Cell therapy can be defined as the transplantation of living cells for the treatment of medical disorders. Three different principles underlie the increasing interest in cell therapy. 1. Transplanted cells used as an “active drug” 2. Transplanted cells used to replace damaged and degenerated tissue. 3. Cells used as a drug delivery vehicle. Promising results have been obtained in pre-clinical and ...
Read Project

 30

 FINISHED 

Réseau d'immunothérapie (IMMUNONET)

Start date: Mar 3, 2009, End date: Dec 30, 2011,

El proyecto IMMUNONET se plantea como objetivo establecer una Red estable de investigación puntera en Inmunoterapia en el SUDOE con un Centro Virtual de apoyo donde distintos grupos de investigadores puedan cooperar y compartir recursos y equipamiento, e intercambiar información con universidades, administraciones públicas, la opinión pública en general y la iniciativa privada. Todos estos objetiv ...
Read Project

 9